GPR120
GPR120 is a receptor for free fatty acids (e.g. omega-3 fatty acids). It plays a role in mediating potent insulin sensitizing and anti-inflammatory response.
Products Related to GPR120(9)
- GC14300GPR120 Compound ACAS: 1599477-75-4Purity: >98.00%
GPR120 Compound A is a selective Gpr120 agonist with a logEC50 of -7.62.
- GC16176GSK 137647CAS: 349085-82-1Purity: >98.00%
GSK 137647 (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively.
- GC31429GPR120 Agonist 2CAS: 1234844-11-1Purity: >99.00%
GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209.
- GC36183GPR120 Agonist 1CAS: 1628448-77-0Purity: >98%
GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC14300 | GPR120 Compound A | 1599477-75-4 | >98.00% | |
GPR120 Compound A is a selective Gpr120 agonist with a logEC50 of -7.62. | ||||
| GC14836 | GPR120 modulator 1 | 1050506-75-6 | >98.50% | |
| GC16016 | GPR120 modulator 2 | 1050506-87-0 | >98% | |
| GC16176 | GSK 137647 | 349085-82-1 | >98.00% | |
GSK 137647 (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. | ||||
| GC16693 | 13Z,16Z-Docosadienoic Acid | 17735-98-7 | >98.00% | |
FFAR4(GPR120) agonist | ||||
| GC18073 | TUG 891 | 1374516-07-0 | >98.00% | |
FFA4 (GPR120) agonist | ||||
| GC31429 | GPR120 Agonist 2 | 1234844-11-1 | >99.00% | |
GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209. | ||||
| GC36183 | GPR120 Agonist 1 | 1628448-77-0 | >98% | |
GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate. | ||||
| GN10112 | Ginsenoside Rb2 | 11021-13-9 | >98.00% | |
